In the aftermath of the massive restructuring programme announced at the time of Q2 15 earnings release, Lundbeck reported strong Q3 numbers, with both revenue and profitability coming in ahead of market expectations. Total revenue was up 7% yoy at LC to DKK3.7bn, driven by (all at LC) Northera (+696%), Abilify Maintena (+182%), Brintellix (+171%), Onfi (+81%), Sabril (+13%) and Xenazine (+7%), along with the divestment gain of DKK113m related to sale of its stake in Naurex, offset to some ex
25 Dec 2015
Early signs of restructuring benefits
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Early signs of restructuring benefits
In the aftermath of the massive restructuring programme announced at the time of Q2 15 earnings release, Lundbeck reported strong Q3 numbers, with both revenue and profitability coming in ahead of market expectations. Total revenue was up 7% yoy at LC to DKK3.7bn, driven by (all at LC) Northera (+696%), Abilify Maintena (+182%), Brintellix (+171%), Onfi (+81%), Sabril (+13%) and Xenazine (+7%), along with the divestment gain of DKK113m related to sale of its stake in Naurex, offset to some ex